SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-Cyclerion Therapeutics Reports Positive Data For MELAS Treatment At Symposium

reuters.com · 06/10/2022 07:21
BRIEF-Cyclerion Therapeutics Reports Positive Data For MELAS Treatment At Symposium

- Cyclerion Therapeutics Inc CYCN:

  • CYCLERION THERAPEUTICS ANNOUNCES POSITIVE TOPLINE CLINICAL DATA FOR CY6463 IN MELAS PATIENTS AT UMDF MITOCHONDRIAL MEDICINE 2022 SYMPOSIUM

  • CYCLERION THERAPEUTICS INC - DATA FROM AN EIGHT-PATIENT, OPEN-LABEL STUDY DEMONSTRATE IMPROVEMENTS ACROSS MULTIPLE BIOMARKERS

  • CYCLERION THERAPEUTICS INC - CY6463 WAS WELL TOLERATED

  • CYCLERION THERAPEUTICS INC - DATA SUPPORT FURTHER DEVELOPMENT OF CY6463 IN CNS DISEASES WITH MITOCHONDRIAL DYSFUNCTION

  • CYCLERION THERAPEUTICS INC - NO REPORTS OF SERIOUS ADVERSE EVENTS (SAES) OR TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS

  • CYCLERION THERAPEUTICS INC - ORAL, ONCE-DAILY ADMINISTRATION PROVIDED EXPECTED CNS EXPOSURE

Source text for Eikon: ID:nGNX4v9ymK

Further company coverage: CYCN


((Reuters.Briefs@thomsonreuters.com;))